For all of the talk about cannabis as a medicine and potential treatment for a wide variety of ailments, from sleep to stress to pain disorders and more, there is a huge missing element. There are almost no FDA-approved cannabis-derived medicines. The potential is very large considering the prevalence and market size of many of these conditions, so why aren’t we seeing more advanced drug candidates and approvals?

They are surely coming, but the hurdles are tremendous. Medical cannabis researchers are working in something of a vacuum, with little historical data to draw from due to years of prohibition. The plant itself is a highly complex assembly of active ingredients, or cannabinoids, and the mechanisms of action are not clearly understood. Genetics can vary widely from plant to plant, even within an accepted strain. Overall it seems there is more we don’t know about the plant than what we do. Data, and testing, and trials, and documentation, and interpretation are all sorely lacking.

RYAH Group, Inc. (CSE: RYAH) is here to change all of that with its suite of proprietary smart devices, patented AI-powered data engine, and its huge (and growing) database of medical cannabis use and its effects. RYAH is involved in several international clinical trials and studies, partnering with researchers to make their investigations efficient, productive, and scientifically relevant. RYAH’s data driven solutions are just the sort of medicine that cannabis researchers should be ordering in their quest to legitimize the plant as a pharmaceutical option.

The Intellectual Property

RYAH has been granted what it believes to be the first patent surrounding the use of artificial intelligence in plant-based medicine, including cannabis. Plant-based medicines are often seen as folk remedies, with practitioners relying on anecdotal evidence and a healthy dose of faith in their potential. There are occasional breakthroughs, like the discovery and development of aspirin, but plant-based medicine is in dire need of scientific documentation. And cannabis is perhaps at the head of that particular line right now.

RYAH CEO Greg Wagner discusses IP, including granted and pending patents.

 RYAH also has patents pending for its suite of connected devices – a pen for tinctures, a patch for transdermal applications, and an inhaler for breathable vapors. The devices offer precise and consistent session management for patients, something which can be difficult for people to achieve. They feed data about the volume and usage into an app, which also offers an easy way for users to record their experiences. The app is tied into the larger RYAH database, and the AI behind the system can make recommendations and observations based not only on the individual’s treatment history but on the history of thousands of other patients.

Put it all together and you have a cannabis- and plant-based medicine compendium of knowledge all wrapped up in the RYAH ecosystem. Patients, doctors, cultivators all benefit from the insights made possible by the system. And researchers are increasingly buying into the concept.

Click here to receive an investor presentation and corporate updates

RYAH and Scientific Research

The potential for RYAH’s proprietary system to move cannabis science forward is tantalizing. The more data is gathered, the more insights can be gained and the larger the body of knowledge becomes. RYAH devices are currently being used in a 5-year study in the United Kingdom, expected to cover thousands of patients and comprising one of the largest research projects to date on the efficacy of cannabis and hemp treatments of chronic pain.

Given the size and scale of the study, RYAH has developed a custom software solution, using OAuth API-integration to protect the privacy of the participants in the study, with the goal of enabling a fully integrated, patient feedback and data collection capability. The combination of an IoT controlled device and direct API data integration with the Clinic’s Electronic Health Record (EHR) system is expected to enable scale and mitigate a number of variables associated with data collection and interpretation which are often performed manually for both volume measurement and patient feedback.

RYAH is also involved in a partnership with the University of Milan to develop a standardized dosing measurement system for dry herb. Think about it – how can doctors prescribe cannabis as a treatment without a method for standardizing the dosage? It’s this sort of foundational science that is needed to move cannabis into the medical mainstream, and RYAH’s system is just the type of solution to provide it.

RYAH is also involved in studies in Jersey, the largest of the Channel Islands between England and France. The company’s devices are central to a pilot study in Italy. The company has agreements in France and New Zealand. RYAH also publishes interesting monthly reports on preferences and tendencies based on user data, giving a glimpse of the kind of insights that can be gained.

In the end, RYAH is aggressively moving forward toward its goal of providing, collating, analyzing, and distributing the scientific data and information necessary to normalize cannabis based medical treatments. The opportunity is tremendous, and the need is dire. Those interested in the future of cannabis as a medicine are encouraged to find out more about RYAH Group Inc. (CSE: RYAH) and follow its progress.

Click here to receive an investor presentation and corporate updates

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

TEL AVIV, Israel, Sept. 7, 2021 /PRNewswire/ — SciSparc Ltd. (OTC Pink: SPRCF), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company”), today announced it has been awarded two patents from the Australian Patent Office and one from the Japanese Patent Office concerning the proprietary compounds and methods underlying the Company’s core technologies (the “Patents”), as listed below:

Australian Patent #AU2016254685A1 and Japanese Patent #2018-507796

Pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.

Australian Patent #AU2016263292A1

Pharmaceutical compositions comprising opioids and N-acylethanolamines, and methods for their use in preventing and treating a variety of opioid- responsive conditions and opioid-related side-effects.

Adi Zuloff-Shani, PhD, Chief Technologies Officer of SciSparc, commented on the announcement, “I am pleased that the Australian and Japanese patent offices have recognized the uniqueness of our pharmaceutical compounds. This is important for the long-term value of any associated products as the Patents establish claims that safeguard the core technologies at the heart of our product pipeline.”

“The approvals strengthen the value of our IP portfolio and build on our competitive advantage in the emerging psycho-pharma market. We filed the International PCT applications to facilitate our ability to participate in the global market. Australia and Japan are the first countries to grant the Patents and I expect Europe, Israel, Canada and China to follow,” Zuloff-Shani concluded.

About SciSparc (OTC Pink:SPRCF):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses expectations regarding the long-term value of SciSparc products and the potential for future patents. The transaction described here may never be consummated and definitive agreement(s) may not be executed, and, if executed, such agreement(s) may be subject to conditions before it can be completed. In addition, the market for products contemplated by the letter of intent is in a period of regulatory and business uncertainty and financial and business results from such businesses are uncertain. Historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with the SEC on March 30, 2021, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
[email protected]
Tel: +972-3-6167055

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Every year, thousands of molecules are being created, synthesized and tested as drug candidates for a vast number of ailments. MagicMed Industries brings this pharmaceutical development approach to the field of psychedelics to create new therapeutic alternatives for patients with brain and mental health indications. However, discovering the right molecules is a massive undertaking. It is essentially trying to find a needle in a haystack. MagicMed Industries has partnered with two leaders in the Artificial Intelligence (AI) space to create a tool known as PsiAI that can reduce the burden of this massive endeavour at lightning speed.

MagicMed’s newly formed partnerships with Cognistx and April 19, are intended to advance psychedelic drug discovery and development through machine learning. Given the potential size of MagicMed’s derivative library, the Psybrary,  it would be nearly impossible to synthesize and screen all of molecules in a timely fashion. Partnering with Cognistx and April 19 will enable MagicMed to develop PsyAI as an in-silico method to screen and discover drug candidates with the greatest potential to treat disease, ultimately enabling the company to expedite valuable molecules to market .

This strategic alliance was formed due to the synergistic culture amongst the partners as well as a shared goal to streamline psychedelic drug discovery and development. Cognistx and April 19 each provide world class expertise and skill sets in developing and deploying machine learning tools successfully within industry as described below.

April 19 is a drug-discovery company driven by AI, which is entirely focused on developing and screening novel compounds for psychedelic medicine. They describe the newfound interest in this field as the “psychedelic renaissance” and believe that it promises to provide required therapies that combat mental illnesses.

April 19 is led by innovators in the artificial intelligence space. Co-founders Dr. Suran Goonatilake and Dr. Richard Dallaway have contributed to the development of AI methods for over 30 years, lending their efforts to sectors such as finance, retail, scientific discovery, and drug discovery. Their focus on deep learning, evolutionary systems, and hybrid systems in large data sets makes them an invaluable partner on this project.

In addition to their experience, these leaders bring added value through their roles outside of April 19. Dr. Goonatilake is a visiting professor at the University College London Centre for Artificial Intelligence, while Dr. Dallaway holds a position as a visiting fellow at the University of Sussex. Both individuals have published many scientific papers, and have a strong entrepreneurial track record in AI-first companies.

The second partner in this project, Cognistx, brings in seasoned AI professionals with connections to Carnegie Mellon University – one of the most prominent Artificial Intelligence and Data Science programs in the world. Additionally, they leverage several years of experience applying AI to a diverse set of industry modalities, including supply chain, cybersecurity, and healthcare. As the field of AI continues to grow, Cognistx has committed to having its finger on the pulse. They remain aware of the state-of-the-art applications in AI, while continuing to evolve in parallel with the industry. With a high-level understanding and experience in applying AI to several industries, Cognistx will undoubtedly be a key partner for MagicMed.

Cognistx is led by co-founders Dr. Eric Nyberg and Sanjay Chopra. Dr. Nyberg serves as the Chief Data Scientist at Cognistx and is a world-renowned AI expert. He is a Professor and Director of the Master of Computational Data Science Program at Carnegie Mellon. Furthermore, Dr. Nyberg was previously a member of the original IBM Watson technology team, where he developed a scalable architecture for multi-strategy question-answering systems. Sanjay Chopra leads Cognistx as the CEO, and has over 28 years of experience in AI, e-commerce, and software development. Chopra also has many years of corporate and entrepreneurial experience. Notably, Chopra licensed Intellions IP to Google, and has been a recipient of Ernst & Young’s Entrepreneur of the Year Regards. These highly knowledgeable thought leaders bring a unique and valuable perspective to the PsyAI project.

Both Cognistx and April 19 bring vast experience and expertise to the table that will be vital for the success of PsyAI, and for MagicMed’s longer-term goal of creating and developing novel psychedelic drug candidates for the treatment of a number of disease indications. The connections both partners bring to academic institutions with world-renowned artificial intelligence programs will be essential, as these partners create the PsiAI tool. When coupled with MagicMed’s Psybrary and expertise within drug research, derivative development, and candidate synthesis this opportunity will have great value for the industry as a whole and for individuals who suffer from mental health illnesses.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Makenzie Branch

Die Psybrary von MagicMed ist eine bemerkenswerte und beeindruckende Leistung, die mehr als geschätzten 125 Millionen Derivaten bis zu deren Patenterteilung Patentschutz bieten könnte. Während 125 Millionen Derivate eine große Zahl ist, sollten dabei zwei Dinge klargestellt werden. Erstens bedeutet diese Zahl nicht, dass das Unternehmen eine kleine Armee von Wissenschaftlern weggesperrt hat, um 125 Millionen verschiedener Moleküle zu synthetisieren. Zweitens hat MagicMed auch nicht 125 Millionen separate und individuelle Patente zum Schutz jedes einzelnen Moleküls angemeldet. Tatsächlich hat MagicMed etwas mehr als 200 der potenziellen Moleküle synthetisiert, die in der Psybrary enthalten sind. Durch das Einreichen von 12 vorläufigen Patenten hat MagicMed den Prozess gestartet, um den Schutz einiger der Moleküle in der Psybrary zu gewährleisten. Eine vorläufige Patentanmeldung ermöglicht einen früheren Anmeldetag zu geringeren Kosten und dient als 12-monatiger Platzhalter, falls sich ein Unternehmen später für einen vollständigen Patentschutz entscheidet. Diese vorläufigen Patente können zu einem späteren Zeitpunkt in nicht vorläufige Patentanmeldungen umgewandelt werden und würden, falls sie erteilt werden, Patentschutz gewähren, der durch den Patentkooperationsvertrag (PCT) international anerkannt ist. Aber was bedeutet das eigentlich? Es kann nützlich sein, sich diese Patente als kompliziert und rechtlich begründet vorzustellen und die eigenen Abenteuergeschichten zu wählen.

Die Struktur eines Patents

Patente sind wie Geschichten auf bestimmte Weise organisiert und stützen sich auf bestimmte Abschnitte, um die Geschichte einer Erfindung zu erzählen. Beide beginnen mit einem Titel und brauchen diesen Titel, um dem Leser eine Vorstellung davon zu geben, worüber er lesen wird. Während eine Geschichte Seiten enthält, auf denen der Autor, der Herausgeber und etwaige Anerkennungen vorgestellt werden, enthält ein Patent Abschnitte, in denen die Erfinder und das Unternehmen, das möglicherweise Rechte an der Erfindung hat sowie frühere oder verwandte Patentanmeldungen aufgeführt sind. Während Literaturstudien die Abschnitte einer Geschichte in einem Diagramm darlegen, erzählt die Struktur eines Patents eine Geschichte, indem es beschreibt, in welchem ​​Sektor oder in welcher Branche eine Erfindung tätig ist, indem die Erfindung zusammengefasst und anschließend eine detaillierte Beschreibung der betreffenden Erfindung bereitgestellt wird. Dies schafft eine wirklich aufregende Geschichte für Menschen, die sich mit Patenten und geistigem Eigentum auskennen. Die Parallele zwischen Geschichten mit frei wählbarem Ende und und Patenten findet sich im Anspruchsabschnitt eines Patents, welcher der wichtigste Abschnitt ist. Wenn ein bestimmtes Molekül wie das Ende einer Geschichte ist, sind die Ansprüche die Aussagen, die den Umfang und den Prozess definieren, die zum Ende hinführen.

Klicken Sie hier, um eine Investorenpräsentation und Unternehmensaktualisierungen zu erhalten

Die Struktur eines Anspruchs

Der erste Teil des Anspruchs, die Präambel, definiert den Umfang der Erfindung und beschreibt, zu welcher Kategorie eine Erfindung gehört: ein physikalischer Gegenstand (eine Vorrichtung oder ein Molekül), ein Verfahren oder eine Art etwas zu tun (wie etwas hergestellt wird) oder eine neuartige Art etwas zu verwenden (häufig zu sehen, wenn Medikamente für neue Indikationen verwendet werden). Der Präambel folgt eine von drei Übergangssätzen: “umfassend”, “bestehend aus” und “wesentlich bestehend aus” und dann der Hauptteil des Anspruchs. Die Übergangssätze sind entscheidend für die Festlegung, wie eng oder breit der Umfang eines Anspruchs sein wird. Die Verwendung des Übergangssatzes “umfassend” ermöglicht es, etwas flexible Parameter im Hauptteil des Anspruchs zu skizzieren. Während “umfassend” etwas flexibel ist, zeigt “bestehend aus” an, dass die Erfindung auf einen spezifischen, engen Satz von Parametern beschränkt ist. Schließlich bedeutet “wesentlich bestehend aus”, dass eine Erfindung durch bestimmte Parameter begrenzt ist oder zusätzliche Komponenten vorhanden sein können, die aber die Natur der Erfindung nicht wesentlich verändern. Wenn ein Anspruch den Übergangssatz “umfassend” verwendet, liefert er genügend Details, um eine grobe Schätzung der Erfindung zu geben, und kann als unabhängiger Anspruch betrachtet werden. Ansprüche, die “bestehend aus” verwenden, definieren eine Erfindung häufig nicht vollständig, verweisen auf einen früheren unabhängigen Anspruch und werden als abhängig angesehen. Unabhängige Ansprüche bieten in Zusammenarbeit eine breite Definition, die dann durch nachfolgende abhängige Ansprüche unterstützt und verfeinert wird.

Wählen Sie Ihr eigenes Ende

Nachdem Sie eine Vorstellung von der Struktur eines Patents und den darin enthaltenen Ansprüchen haben, können wir die Analogie eines Romans mit frei wählbarem Ende erneut betrachten. In vielen Geschichten wird einem Helden eine etwas vage Aufgabe zugewiesen, die „Suche“, die unter anderem durch „Ehre“, „Gefahr“ und „jemanden, der gerettet werden muss“ gekennzeichnet ist. Diese Suche ähnelt einem unabhängigen Anspruch. Sie enthält einige grobe Parameter, die dem Bestreben einen gewissen Spielraum bieten, aber insgesamt fehlen Einzelheiten. Nachdem dem Helden eine Aufgabe zugewiesen wurde, trifft er normalerweise auf Nebencharaktere, die jeweils ihre eigene Meinung zu „Ehre“, „Gefahr“ und „jemandem, der gerettet werden muss“ haben, was den Umfang der Aufgabe weiter definiert. Zum Beispiel könnte “Ehre” bedeuten, ein Dorf zu retten oder ein persönliches Opfer durch den Helden zu bringen, “Gefahr” könnte bedeuten, eine Naturkatastrophe zu verhindern oder ein gefährliches Monster zu töten, und “jemand, der gerettet werden muss” könnte buchstäblich jeder sein. In jedem Fall ähneln diese Zeichen und die von ihnen bereitgestellte Struktur abhängigen Ansprüchen. Abhängig von der groben Definition einer Aufgabe, welchen Nebencharakteren der Held begegnet und welche Meinungen sie zu den Ereignissen der Aufgabe haben, wird der Held mit einer Vielzahl von Reisen konfrontiert, die alle als “Aufgabe“ betrachtet werden können. Dieselbe Variabilität spiegelt sich in der Definition des Umfangs einer Erfindung und deren möglichen Derivaten wider.

Diese Variabilität gilt insbesondere für Arzneimittel mit einer ähnlichen Kernstruktur. Benzoxazolderivate bilden eine vielfältige Gruppe von Arzneimitteln mit medizinischen Eigenschaften, die von der Abtötung von Bakterien bis zur Schmerzlinderung reichen und alle auf einem einfacheren Molekül, Benzoxazol, basieren. Eine Kernstruktur kann chemisch verändert werden, sodass bestimmte chemische Gruppen an einem bestimmten Ort hinzugefügt werden. Ein Molekül und die verschiedenen chemischen Gruppen, die hinzugefügt werden, sind wie die Aufgabe und ihre vagen Anforderungen. Die chemischen Gruppen können viele verschiedene und verwandte Strukturen enthalten, sind durch die Ansprüche definiert und legen fest, welche Derivate zu einer Erfindung gehören. Boxazomycin A und B sind zwei Arten von Antibiotika mit Benzoxazolderivaten, die durch Modifikation einer einzelnen chemischen Gruppe hergestellt werden (innerhalb des roten Kreises mit „R“ bezeichnet). Während dieses Beispiel einer Gruppe mit zwei Möglichkeiten und zwei möglichen Derivaten einfach ist, können einigen Molekülen mehrere Gruppen hinzugefügt werden und durch Ansprüche mit 100 oder 1000 akzeptablen Alternativen begrenzt werden. Ansprüche, die den Umfang einer Erfindung unter Verwendung verwandter Modifikationen erweitern, sind als Markush-Ansprüche bekannt und in der pharmazeutischen Industrie üblich. Ein Kernmolekül mit 3 R-Gruppen mit jeweils 100 möglichen Modifikationen erzeugt eine Million verschiedene Kombinationen (100 * 100 * 100). Verschiedene psychedelische Strukturen mit jeweils zahlreichen möglichen Modifikationen ermöglichen es MagicMed, verschiedene Patente einzureichen und Millionen verschiedener Moleküle zu schützen. Ähnlich wie eine Bibliothek, die ihre Büchersammlung erweitert, wird MagicMed sein geistiges Eigentum weiter ausbauen, sein Portfolio um weitere Patente erweitern und die Psybrary erweitern, um noch mehr patentgeschützte Moleküle aufzunehmen.

Klicken Sie hier, um die Investorenpräsentation und Unternehmensaktualisierungen zu erhalten

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

When you’ve got something great, it may take a little bit of time for people to learn about it, but once word starts getting around, it can yield a windfall of interest. That’s the case with Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and its DehydraTECH technology that enhances qualities and uptake of all sorts of lipophilic (fat-based) molecules. As such, companies from diverse businesses have partnered with Lexaria recently, including Hill Street Beverage last week.

So What’s the Big Deal with DehydraTECH?

The human body has a natural digestive process that is quite proficient at filtering molecules to ensure safe delivery of only beneficial substances. In scientific nomenclature, a molecule (an oral medicine for example) actually reaching the human bloodstream is referred to as “bioavailability” and it can be a real challenge to do so.

Click on the Video for Education on Lexaria’s DehydraTECH technology.

DehydraTECH is an efficient Trojan horse for getting molecules delivered in oral form around the filtering process of liver metabolism and into the bloodstream. Lexaria accomplishes this by joining the payload – albeit a vitamin, active pharmaceutical ingredient, nicotine, cannabinoid, etc. – with a microscopic particle of a special type of fat known as LCFA’s (long chain fatty acids). Upon ingestion, the body detects the LCFA, not the molecule hidden alongside. There are a multitude of positive results from this technology, which have been verified through lab and human studies.

Click Here to View Lexaria’s Investor Presentation

For starters, many beneficial molecules taste and smell horrible. DehydraTECH eliminates that problem, making them palatable without using sugar like most competitors do today. Even more importantly, the bioavailability profile changes dramatically. The time it takes to feel the effect can be shaved to as little as 10 minutes (as little as 2 minutes in animal testing) from the natural metabolic process that typically takes around 90 minutes. Furthermore, bioavailability can surge as much as 10-fold, meaning the consumer is getting more of what they want and need faster.

Opportunities Abound

The beauty of the DehydraTECH technology is that it is easily and cost-effectively implemented into existing manufacturing operations. It appeals to a diverse group of customers because of the many different types of molecules for endless applications. As detailed in the company’s presentation, from pills to coffee, DehydraTECH is a highly versatile drug delivery method.

Some of the initial targets being focused on are cannabinoids, NSAIDs such as ibuprofen (non-steroidal anti-inflammatory drugs), vitamins and nicotine. The opportunity to genuinely disrupt the nearly $1 trillion market with the world’s first ingestible nicotine product did not escape Marlboro owner Altria (NYSE: MO). In January, the international tobacco behemoth agreed to put up $12 million for R&D and product development for oral, reduced risk nicotine consumer products using DehydraTECH and agreed to pay Lexaria a royalty on products sold with DehydraTECH technology.

July Big Month for New Partners

The cannabis market is booming, as more health conscious consumers look to the plant for all of its therapeutic effects. In particular, people are looking to cannabidiol (CBD), a prominent cannabinoid found in hemp and cannabis trumpeted for its benefits for treating everything from dry skin to epileptic seizures.

The legalization of hemp at the start of the year thanks to the passage of the U.S. Farm Bill has the hemp market abuzz and Lexaria is in the thick of it. Early in July, the company’s subsidiary Lexaria Hemp Corp. entered a 5-year agreement to provide DehydraTECH technology to Nic’s Beverages Ltd for use in CBD-based beverages to be produced and sold throughout America.

Nic’s is the fourth company (3 in the U.S. and 1 in Canada) to license the technology for beverages. Nic’s plan is to begin making ready-to-drink cold brew coffees enhanced with CBD from multi-spectrum hemp oil.

“DehydraTECH technology is perfect in allowing us to deliver CBD from hemp oil with zero impact on our cold brewed coffee’s outstanding aroma or flavor,” commented Nic’s CEO John Goodpasture.

A day after the Nic’s deal was disclosed, Lexaria said it inked a 5-year deal to provide DehydraTECH to B2B manufacturing company Universal Hemp LLC. Universal Hemp will be using the technology for its hemp-derived CBD bulk ingredients it supplies to the nutraceutical and consumer packaged goods industries throughout the U.S. and Canada.

“In terms of bioavailability, shelf stability and taste, [DehydraTECH] is the best performing technology in the market, hands down,” said Chad Kahunahana, CEO and Founder of Universal Hemp about the partnership.

Future royalties and other financial terms were kept confidential, but it was revealed that the deal has minimum down payments over the life of the contract of US$3.75 million.

Lexaria kept the momentum going all month, announcing a 10-year joint manufacturing partnership (JMP) with Hill Street Beverage Co. (TSX-V: BEER) to create commercial products utilizing DehydraTECH. Per the pact, the companies will work together to make THC cannabis and/or CBD hemp powder for all new (and yet unnamed) consumer products in the form of tablets, capsules and packets.

Click Here to View Lexaria’s Investor Presentation

The JMP will also produce similar powders as a bulk ingredient for manufacturing processes for sale to other licensed producers seeking to use Lexaria’s advanced infusion technologies to create their own wide variety of products for sale within Canada.

Hill Street is in the midst of completing the acquisition of OneLeaf Cannabis. Manufacturing of the new goods, which will be handled by Hill Street and utilize DehydraTECH in the process, is expected to be done at OneLeaf’s cultivation and processing facility in Regina, Saskatchewan, pending all Health Canada approvals.

For its part in bringing DehydraTECH to the table, Lexaria is entitled to 50% of the new company’s profits.

The companies are making the moves now to be properly positioned when cannabis-infused edibles become legal throughout Canada later this year.

The JMP may be new, but the relationship between Hill Street and Lexaria is not. Hill Street had previously licensed the DehydraTECH technology for CBD-infused beverage sales in Canada. Last week, a new 10-year agreement was forged giving Hill Street global rights on a semi-exclusive basis.

It seems that CEO’s of consumer product companies are enamored with DehydraTECH: “Lexaria has proven themselves time and again to be the ideal infusion platform for our products,” commented Hill Street’s Chairman and CEO, Terry Donnelly.

Under the terms of the agreement, Hill Street is paying Lexaria US$1.8 million in BEER stock, most up front, with the remainder owed upon meeting milestones for entering new international markets.

Lexaria announced in August that they’ve received a cannabis R&D license from Health Canada that does not expire until August 2023, allowing the company for the first time ever to place its state-of-the-art laboratory into operation and accelerate a truly impressive research program.

“Lexaria has evolved so rapidly and achieved so much in the past eight months, that we are nearly unrecognizable compared to the end of 2018,” said Chris Bunka, Chief Executive Officer of Lexaria. “We’re signing new customers at ten times the rate of previous years; we’ve partnered with one of the largest companies in North America; additionally, we’ve just completed construction of one of the most advanced labs in the industry. 2019 has been a fabulous year so far and we think it will only get better, and drive strong new revenues and advances into 2020 and far beyond.”

The most recent sign of those advances is the appointment of Mr. Brian Quigley to their board of directors. Mr. Quigley most recently spent 16 years at Altria Group, 7 of those years were spent as President and Chief Executive Officer for U.S. Smokeless Tobacco and Nu-Mark, Altria’s innovation company. It was during that period of time that the existing business relationship between Altria and Lexaria was negotiated.

“I am thrilled to be joining the already strong team at Lexaria Bioscience. From my first engagement with Chris, it was clear to me that Lexaria and its leadership team is positioned to create change through innovation in both the Cannabis and Nicotine space. It is an honor to join this team after forging such a strong partnership with them during my time with Altria.”

Consumer Products Company? Licensing Company? Try Both.

Because Lexaria has two brands of its own: ViPova (a beverage lineup of teas and coffee) and both TurboCBD capsules and ChrgD+ powdered drink mix, they sometimes get lumped in with other CBD consumer brands companies. Adding in the new venture with Hill Street adds to that assumption.

Fact is though, technology licensing is at the core of Lexaria’s business. Candidly, it is a far more lucrative business too, with margins generally 90+%. With a robust patent estate of about a dozen issued patents and more than 60 additional pending, management has built itself a strong position with a better solution than sweeteners and chemicals for any and all ingestible products by merely adding one step to the manufacturing process.

When more companies continue to learn that they can add DeyhydraTECH to their operations to make lipophilic compounds palatable with superior bioavailability for only a fraction of a penny per product serving, there is likely going to be more companies knocking on Lexaria’s door.

Click Here to View Lexaria’s Investor Presentation

Click Here For More Information on Lexaria Bioscience Corp.

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

About Ash Stringer